Ecotypes of triple-negative breast cancer in response to chemotherapy
The Shift from “One-Size-Fits-All” to Cellular Mapping For decades, treating Triple-Negative Breast Cancer (TNBC) has felt like fighting a ghost. Because TNBC lacks the three most common receptors—estrogen, progesterone, and HER2—doctors have historically relied on a broad-spectrum “sledgehammer” approach: chemotherapy. While effective for some, nearly half of patients don’t respond as hoped. The tide is … Read more